BLTE
Companies
NASDAQ
Belite Bio, Inc.
Health Care
$60.36
-$2.74 (-4.34%)
Price Chart
Overview
About BLTE
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Market Cap
$1.4B
Volume
1.5M
Avg. Volume
1.8M
P/E Ratio
-70.09375
Dividend Yield
0.00%
Employees
13.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.72
Low Correlation
Volatility
High (0.58)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BLTE shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025